Related Experiment Videos

The fetal valproate syndrome

Insights

Prenatal exposure to sodium valproate (valproic acid) can cause a distinct facial phenotype in children. This pattern of facial changes, along with other birth defects, highlights potential risks of in utero drug exposure.

Area of Science:

  • Teratology
  • Developmental Pediatrics
  • Clinical Genetics

Background:

  • Sodium valproate (valproic acid) is a widely used antiepileptic and mood-stabilizing drug.
  • Concerns exist regarding potential teratogenic effects of valproate when used during pregnancy.

Purpose of the Study:

  • To describe the facial phenotype and associated birth defects in children exposed to sodium valproate in utero.
  • To identify a consistent pattern of dysmorphic features linked to prenatal valproate exposure.

Main Methods:

  • Retrospective evaluation of seven children with documented in utero exposure to sodium valproate.
  • Detailed clinical assessment and documentation of facial features and other congenital anomalies.

Main Results:

  • All seven children exhibited a consistent facial phenotype.
  • Observed features included epicanthal folds, flat nasal bridge, small upturned nose, long philtrum, and downturned mouth.
  • Four children presented with additional birth defects, including hypospadias, strabismus, psychomotor delay, nystagmus, and low birth weight.

Conclusions:

  • Prenatal exposure to sodium valproate is associated with a recognizable pattern of facial dysmorphism.
  • The findings underscore the importance of monitoring for birth defects in offspring of mothers using valproate during pregnancy.

Related Concept Videos